Provides supplemental IFRS materials for the second quarter of the fiscal year ending March 2027. Discloses cumulative-period and quarterly revenue, operating income, interim profit, earnings per share, and sales by region and major products. Some indicators suggest potential revisions to full-year forecasts and note currency exchange impacts. New drug development status is also disclosed.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4503","jir_company_name":"Astellas Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4503-20261104-02.pdf","jir_short_summary":"Provides supplemental IFRS materials for the second quarter of the fiscal year ending March 2027. Discloses cumulative-period and quarterly revenue, operating income, interim profit, earnings per share, and sales by region and major products. Some indicators suggest potential revisions to full-year forecasts and note currency exchange impacts. New drug development status is also disclosed.","jir_summary":"### Performance Overview\nThese materials provide supplemental information for the second quarter of the fiscal year ending March 2027. Revenue shows an increasing trend compared with FY26\/3 (cumulative segmentation such as 63 is suggested but exact values are unclear). Sales breakdowns by region and major products are disclosed. Core-based metrics are also presented, and estimated currency impacts (USD\/JPY, EUR\/JPY) are shown. Profitability generally shows an improving trend, but there is room for revision to full-year forecasts.\n\n### New Drug Development Status and Key Strategic Products\nNew drug development information breaks down regional sales for major products such as PADCEV, IZERVAY, XOSPATA, and XTANDI, with noted changes as of October 2026. Sales contributions from key strategic products remain solid, suggesting global market expansion. However, some development-stage items show regional differences, and approvals or launch timing could cause ongoing variability in financial performance.","jir_financial_highlights":"Revenue (full year): 21,392 (vs FY26\/3 8.9% increase)\nRevenue (2Q cumulative): 12,709 (vs FY26\/3 23.4% increase)\nOperating income (full year): 3,950 (Full-year forecast in supplemental data includes ranges such as 4,600 ~ 4,600-4,600)","jir_category":"","jir_hashtags":"#IRearnings, #NewDrugDevelopmentStatus, #GlobalSalesComposition","jir_key_figures":"Revenue (cumulative period): 12,709 (hundred million yen) Change rate 23.4%\nGross profit (cumulative period): 10,230 (hundred million yen)\nOperating income (cumulative period): 3,166 (hundred million yen) A comparison table shows 4,249 (hundred million yen) on an adjusted core basis","jir_meta_title":"Unknown: Supplemental Materials for Q2 FY2027 | Revenue and Major Product Trends","jir_meta_description":"Supplemental materials for Q2 FY2027 disclose cumulative revenue, operating income, sales by region and major products. They reference currency impacts and potential revisions to full-year forecasts, and include new drug development updates.","jir_og_title":"Key Points from Q2 FY2027 Supplemental Financial Materials","jir_og_description":"Summary of cumulative revenue and profit metrics, sales by region and product, currency impacts, and new drug development status. Watch for future full-year forecast trends.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6911,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-141148","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n